The Cluster Headache Syndrome (Cluster Headache) drugs in development market research report provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Cluster Headache), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cluster Headache Syndrome (Cluster Headache). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued products.

GlobalData tracks 21 drugs in development for Cluster Headache Syndrome (Cluster Headache) by 20 companies/universities/institutes. The top development phase for Cluster Headache Syndrome (Cluster Headache) is preclinical with seven drugs in that stage. The Cluster Headache Syndrome (Cluster Headache) pipeline has 21 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Cluster Headache Syndrome (Cluster Headache) pipeline products market are: Ceruvia Lifesciences, Lusaris Therapeutics and Amgen.

The key targets in the Cluster Headache Syndrome (Cluster Headache) pipeline products market include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A), 5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D), and 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A).

The key mechanisms of action in the Cluster Headache Syndrome (Cluster Headache) pipeline product include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Agonist with six drugs in Phase I. The Cluster Headache Syndrome (Cluster Headache) pipeline products include nine routes of administration with the top ROA being Oral and two key molecule types in the Cluster Headache Syndrome (Cluster Headache) pipeline products market including Small Molecule, and Monoclonal Antibody.

Cluster Headache Syndrome (Cluster Headache) overview

Cluster headache is pain that occurs along one side of the head. It frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain; red eyes; runny nose; excessive tearing; and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

For a complete picture of Cluster Headache Syndrome (Cluster Headache)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.